Biotechnology News and Research

RSS

RegeneRx completes RGN-259 Phase 2 trial on dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. today announced that treatment and follow-up have been completed on 69 patients in the Company's Phase 2 clinical trial with RGN-259 for the treatment of dry eye syndrome, five more than the number of evaluable patients contemplated in the trial's protocol.

26 Sep 2011

EMA CHMP adopts positive opinion for Soliris to treat atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that the therapeutic indication for Soliris® (eculizumab) be extended to include the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS) in Europe.

23 Sep 2011

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Amgen announced today that data from XGEVA (denosumab) and Vectibix (panitumumab) studies will be presented at the 2011 European Multidisciplinary Cancer Congress, Sept. 23 - 27, 2011, in Stockholm, Sweden.

23 Sep 2011

MannKind proposes to offer senior secured discount notes due 2017

MannKind Corporation today announced that it proposes to offer, subject to market conditions, senior secured discount notes due 2017 expected to yield gross proceeds of approximately $370.0 million.

23 Sep 2011

Nigeria expected to sign agreement with UNESCO for international biotech center targeting food security, disease

The Nigerian government is expected to sign an agreement with UNESCO at the 36th session of the General Conference of UNESCO, which begins next month, for an international biotechnology center that will focus on strengthening food safety, tropical disease research and the conservation of bio-resources across Africa, SciDev.Net reports, adding that "UNESCO's executive board approved the establishment of the center earlier this year."

23 Sep 2011

Preclinical data from two Pulmatrix's PUR118 study to be presented at ERS 2011

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that data from two preclinical studies of its inhaled clinical drug candidate, PUR118, will be presented at The European Respiratory Society Annual Congress (ERS 2011), being held September 24-28, 2011, in Amsterdam, Netherlands.

23 Sep 2011

USPTO issues patent for Lixte's LB-100 to treat cancer

John S. Kovach, M.D., Chair, Board of Directors and CEO of Lixte Biotechnology Holdings, Inc., announces that the United States Patent and Trademark Office awarded a patent on its lead compound, LB-100, as well as a number of structurally related compounds, which has shown promising anti-cancer activity.

23 Sep 2011

AGTC receives FFB grant to evaluate gene therapy treatment for X-linked Retinoschisis

Applied Genetic Technologies Corporation, a privately-held, clinical stage biotechnology company developing novel systems to deliver human therapeutics, announces that it has received a grant of $1.5 million from the Foundation Fighting Blindness to fund a pre-clinical trial evaluating the safety and efficacy of a gene therapy treatment for X-linked Retinoschisis (XLRS), a genetic eye disease affecting over 35,000 patients in the US and Europe.

22 Sep 2011

ACT receives UK MHRA clearance for hESC-derived RPE cell trial for Stargardt's Macular Dystrophy

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it has received clearance from the U.K. Medicines and Healthcare products Regulatory Agency to begin treating patients as part of a Phase 1/2 clinical trial for Stargardt's Macular Dystrophy using retinal pigment epithelium (RPE) derived from human embryonic stem cells.

22 Sep 2011

Palatin's fourth quarter net loss decreases to $3.3 million

Palatin Technologies, Inc., a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, today announced results for its fourth quarter and fiscal year ended June 30, 2011.

22 Sep 2011

Zymeworks announces completion of $8.1M financing

Zymeworks Inc., a privately held biotherapeutics company focused on the development of best-in-class antibody and next generation protein-based therapeutics, today announced the completion of a financing totaling $8.1 million.

22 Sep 2011

Quidel, Life Technologies to distribute and commercialize molecular diagnostics in Europe

Life Technologies Corporation today announced that the company has signed an agreement with Quidel Corporation to distribute and commercialize molecular diagnostic assays for the European market.

22 Sep 2011

Theraclone initiates TCN-032 Phase 1 trial in influenza A

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today first dosing of subjects in a Phase 1 clinical trial of TCN-032, a broadly protective, fully human monoclonal antibody for the treatment of influenza A virus.

22 Sep 2011

Silence Therapeutics reports revenue of £354,078 for six months ended 30 June 2011

Silence Therapeutics Plc, a leading international RNAi therapeutics company, today provides a corporate update and announces its interim results for the six months ended 30 June 2011.

21 Sep 2011

Gilead’s new 4 in 1 combo HIV pill works

Gilead Sciences Inc's four-drug experimental HIV pill worked as well as a regimen containing protease inhibitor Reyataz in the second pivotal trial of the drug, the company announced this Monday. Although the trial succeeded, it did not show the experimental pill, called the Quad, was superior to the Reyataz regimen and Gilead shares fell less than a percentage point.

20 Sep 2011

New York Times examines possible entry into global market of generic drugs for NCDs

The New York Times describes how, as the U.N. begins its meeting on non-communicable diseases (NCDs), Chinese and Indian generic drug makers "say they are on the verge of selling cheaper copies" of costly biotech medications used to treat cancers, diabetes, arthritis and other chronic illnesses.

20 Sep 2011

Conference to discuss how research, technology and innovation can contribute to food for all

The conference, hosted by the European Commission's in-house science service, the Joint Research Centre (JRC), will discuss how research, technology and innovation can contribute to food for all. It will look at the best way to foster sustainability of food supply on a global scale.

20 Sep 2011

Vitrolife obtains Chinese SFDA approval for aspiration needles and micropipettes

Vitrolife has obtained regulatory approval from the Chinese SFDA (State Food and Drug Administration) for aspiration needles and micropipettes used for infertility treatment.

20 Sep 2011

NovaSterilis awarded patent for novel preparation and sterilization of ‘Green State’ devices

NovaSterilis Inc. has been granted US Patent No 7,988,892. The patent, dated August 2, 2011 is entitled “Preparation and Sterilization of Green State Devices Using a Supercritical Fluid Sterilant.”

19 Sep 2011

Amgen's Prolia receives FDA approval for new indications to treat cancer patients

Amgen today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for Prolia® (denosumab) as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer and as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer.

19 Sep 2011

Biotechnology News and Research

RegeneRx completes RGN-259 Phase 2 trial on dry eye syndrome

EMA CHMP adopts positive opinion for Soliris to treat atypical hemolytic uremic syndrome

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

MannKind proposes to offer senior secured discount notes due 2017

Nigeria expected to sign agreement with UNESCO for international biotech center targeting food security, disease

Preclinical data from two Pulmatrix's PUR118 study to be presented at ERS 2011

USPTO issues patent for Lixte's LB-100 to treat cancer

AGTC receives FFB grant to evaluate gene therapy treatment for X-linked Retinoschisis

ACT receives UK MHRA clearance for hESC-derived RPE cell trial for Stargardt's Macular Dystrophy

Palatin's fourth quarter net loss decreases to $3.3 million

Zymeworks announces completion of $8.1M financing

Quidel, Life Technologies to distribute and commercialize molecular diagnostics in Europe

Theraclone initiates TCN-032 Phase 1 trial in influenza A

Silence Therapeutics reports revenue of £354,078 for six months ended 30 June 2011

Gilead’s new 4 in 1 combo HIV pill works

New York Times examines possible entry into global market of generic drugs for NCDs

Conference to discuss how research, technology and innovation can contribute to food for all

Vitrolife obtains Chinese SFDA approval for aspiration needles and micropipettes

NovaSterilis awarded patent for novel preparation and sterilization of ‘Green State’ devices

Amgen's Prolia receives FDA approval for new indications to treat cancer patients

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News